Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
9 pending office actions • 9 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Massachusetts Eye and Ear Infirmary has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 8 distinct examiners and 8 distinct art units, indicating a broad prosecution workload with no concentration by examiner or technical group.
FUBARA, BLESSING M is the busiest examiner, with 1 pending matter. Because each matter follows its own examination path, portfolio management should emphasize disciplined docket control, individualized claim analysis, and comparison of recurring issues at the technology level rather than reliance on examiner continuity.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| §112 only | 2 (22%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 5 (56%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 1 | 62.2% | +34.1% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
| BURKE, THOMAS P | 1 | 43.9% | +21.7% |
| ZAHORIK, AMANDA MARY | 1 | 58.3% | +49.3% |
| DIOP, FATIMATA SAHRA | 1 | 68.6% | +38.0% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
| KOHUTKA, BROOKE NICOLE | 1 | 37.5% | +92.3% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023566 | DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY | DIOP, FATIMATA SAHRA | 19d overdue |
| 18284637 | SUBMUCOSAL IMPLANTABLE DRUG DELIVERY APPARATUSES, SYSTEMS, AND METHODS | BURKE, THOMAS P | 5d |
| 18595527 | AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA | VIVLEMORE, TRACY ANN | — |
| 17996715 | SYSTEMS AND METHODS FOR CONTROLLING THE SPREAD OF AIRBORNE MATERIALS DURING CLINICAL OR LABORATORY PROCEDURES | KOHUTKA, BROOKE NICOLE | — |
| 17920088 | HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION | SPENCER, ANDREA LYNNE MORRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275146 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | ZAHORIK, AMANDA MARY | 24d overdue |
| 18023566 | DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY | DIOP, FATIMATA SAHRA | 19d overdue |
| 18284637 | SUBMUCOSAL IMPLANTABLE DRUG DELIVERY APPARATUSES, SYSTEMS, AND METHODS | BURKE, THOMAS P | 5d |
| 18611374 | APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF | WANG, CHANG YU | 84d |
| 18825450 | Biodegradable Implant for Sustained Trans-Nasal Delivery of Therapeutic Agents to the Brain | FUBARA, BLESSING M | — |
| 17921971 | TARGETED BASE EDITING OF THE USH2A GENE | VIJAYARAGHAVAN, JAGAMYA NMN | — |
| 17996715 | SYSTEMS AND METHODS FOR CONTROLLING THE SPREAD OF AIRBORNE MATERIALS DURING CLINICAL OR LABORATORY PROCEDURES | KOHUTKA, BROOKE NICOLE | — |
| 17920088 | HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION | SPENCER, ANDREA LYNNE MORRIS | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1675 | 1 |
| 1638 | 1 |
| 3741 | 1 |
| 1636 | 1 |
| 3783 | 1 |
| 1633 | 1 |
| 3791 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18825450 | Biodegradable Implant for Sustained Trans-Nasal Delivery of Therapeutic Agents to the Brain | FUBARA, BLESSING M | 1613 | §102§103DP | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18611374 | APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF | WANG, CHANG YU | 1675 | §112 | Non-Final OA | 84d | Pending | Mar 20, 2024 |
| 18595527 | AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA | VIVLEMORE, TRACY ANN | 1638 | §103§112 | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18284637 | SUBMUCOSAL IMPLANTABLE DRUG DELIVERY APPARATUSES, SYSTEMS, AND METHODS | BURKE, THOMAS P | 3741 | §102§103 | Final Rejection | 5d | Pending | Sep 28, 2023 |
| 18275146 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | ZAHORIK, AMANDA MARY | 1636 | §103 | Final Rejection | 24d overdue | Pending | Jul 31, 2023 |
| 18023566 | DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY | DIOP, FATIMATA SAHRA | 3783 | §102§103 | Final Rejection | 19d overdue | Pending | Feb 27, 2023 |
| 17921971 | TARGETED BASE EDITING OF THE USH2A GENE | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §112 | Non-Final OA | — | Pending | Oct 27, 2022 |
| 17996715 | SYSTEMS AND METHODS FOR CONTROLLING THE SPREAD OF AIRBORNE MATERIALS DURING CLINICAL OR LABORATORY PROCEDURES | KOHUTKA, BROOKE NICOLE | 3791 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17920088 | HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION | SPENCER, ANDREA LYNNE MORRIS | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMassachusetts Eye and Ear Infirmary has 9 pending office actions as of October 2026, spread across 9 art units and 9 examiners.
Blessing M Fubara has the most, with 1 of Massachusetts Eye and Ear Infirmary's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
